{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:45Z","timestamp":1784408865184,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,29]]},"DOI":"10.7759\/cureus.85011","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:54:42Z","timestamp":1748505282000},"source":"Crossref","is-referenced-by-count":1,"title":["Brain Metastases From HER2 Breast Cancer That Achieved Complete Response With Trastuzumab Deruxtecan Without Any Local Treatment"],"prefix":"10.7759","author":[{"given":"Katsuhiro","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432442","article-title":"Systemic therapy in breast cancer","volume":"44","author":"Corti C","year":"2024","unstructured":"Corti C, Batra-Sharma H, Kelsten M, Shatsky RA, Garrido-Castro AC, Gradishar WJ. Systemic therapy in breast cancer. Am Soc Clin Oncol Educ Book. 2024, 44:10.1200\/EDBK_432442","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102233","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis","volume":"9","author":"Michelon I","year":"2024","unstructured":"Michelon I, Vilbert M, Marinho AD, et al.. Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis. ESMO Open. 2024, 9:10.1016\/j.esmoop.2024.102233","journal-title":"ESMO Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00584-5","article-title":"Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM)","volume":"9","author":"Niikura N","year":"2023","unstructured":"Niikura N, Yamanaka T, Nomura H, et al.. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM). NPJ Breast Cancer. 2023, 9:82. 10.1038\/s41523-023-00584-5","journal-title":"NPJ Breast Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae123","article-title":"Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases","volume":"26","author":"Bartsch R","year":"2024","unstructured":"Bartsch R, Berghoff AS, Furtner J, et al.. Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neuro Oncol. 2024, 26:2305-15. 10.1093\/neuonc\/noae123","journal-title":"Neuro Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.118612","article-title":"64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer","volume":"54","author":"Tamura K","year":"2013","unstructured":"Tamura K, Kurihara H, Yonemori K, et al.. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med. 2013, 54:1869-75. 10.2967\/jnumed.112.118612","journal-title":"J Nucl Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02822","article-title":"Pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and HER2-positive metastatic breast cancer: primary analysis of a phase II study","volume":"39","author":"Lin NU","year":"2021","unstructured":"Lin NU, Pegram M, Sahebjam S, et al.. Pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and HER2-positive metastatic breast cancer: primary analysis of a phase II study. J Clin Oncol. 2021, 39:2667-75. 10.1200\/JCO.20.02822","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100114","article-title":"Evolution of overall survival and receipt of new therapies by subtype among 20\u2009446 metastatic breast cancer patients in the 2008-2017 ESME cohort","volume":"6","author":"Grinda T","year":"2021","unstructured":"Grinda T, Antoine A, Jacot W, et al.. Evolution of overall survival and receipt of new therapies by subtype among 20\u2009446 metastatic breast cancer patients in the 2008-2017 ESME cohort. ESMO Open. 2021, 6:10.1016\/j.esmoop.2021.100114","journal-title":"ESMO Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0619-y","article-title":"Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort","volume":"121","author":"Darlix A","year":"2019","unstructured":"Darlix A, Louvel G, Fraisse J, et al.. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019, 121:991-1000. 10.1038\/s41416-019-0619-y","journal-title":"Br J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.9861","article-title":"Chemotherapy delivery issues in central nervous system malignancy: a reality check","volume":"25","author":"Muldoon LL","year":"2007","unstructured":"Muldoon LL, Soussain C, Jahnke K, et al.. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007, 25:2295-305. 10.1200\/JCO.2006.09.9861","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.2713","article-title":"Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update","volume":"36","author":"Ramakrishna N","year":"2018","unstructured":"Ramakrishna N, Temin S, Chandarlapaty S, et al.. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update. J Clin Oncol. 2018, 36:2804-7. 10.1200\/JCO.2018.79.2713","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial","volume":"316","author":"Brown PD","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, et al.. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016, 316:401-9. 10.1001\/jama.2016.9839","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-0060-9","article-title":"The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline","volume":"96","author":"Gaspar LE","year":"2010","unstructured":"Gaspar LE, Mehta MP, Patchell RA, et al.. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010, 96:17-32. 10.1007\/s11060-009-0060-9","journal-title":"J Neurooncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.020","article-title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606)","volume":"31","author":"Montemurro F","year":"2020","unstructured":"Montemurro F, Delaloge S, Barrios CH, et al.. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(\u2606). Ann Oncol. 2020, 31:1350-8. 10.1016\/j.annonc.2020.06.020","journal-title":"Ann Oncol"},{"key":"ref14","unstructured":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae). central nervous system cancers. (2024). Accessed: January 21, 2025: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-016-9619-z","article-title":"Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases","volume":"35","author":"Liu MC","year":"2016","unstructured":"Liu MC, Cort\u00e9s J, O'Shaughnessy J. Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. Cancer Metastasis Rev. 2016, 35:323-32. 10.1007\/s10555-016-9619-z","journal-title":"Cancer Metastasis Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer CE","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, et al.. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006, 355:2733-43. 10.1056\/NEJMoa064320","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga J","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB, et al.. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012, 366:109-19. 10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al.. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367:1783-91. 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s J","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, et al.. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022, 386:1143-54. 10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy RK","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, et al.. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020, 382:597-609. 10.1056\/NEJMoa1914609","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/368031-brain-metastases-from-her2-breast-cancer-that-achieved-complete-response-with-trastuzumab-deruxtecan-without-any-local-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:54:43Z","timestamp":1748505283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/368031-brain-metastases-from-her2-breast-cancer-that-achieved-complete-response-with-trastuzumab-deruxtecan-without-any-local-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.85011","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,29]]}}}